Legemiddel mot influensa - Relenza

Relenza - virkningsmekanisme

Influensaviruset angroper, nye dannes og spres.

Influensaviruset angriper epitelceller i luftveiene

Spreding uten Relenza:

Nye virus dannes og spres. Enzymet neuraminidase fremmer frisettingen av nydannede virus fra infiserte celler.

Ingen spredning med Relenza:

Relenza er en selektiv neuraminidasehemmer og hindrer frisetting av nye influenzavirus.

 

Relenza virker lokalt i luftveiene

  • Relenza stopper spredningen av influensaviruset der viruset angriper og formerer seg - i luftveiene3,4.
  • Relenza inhaleres direkte til luftveiene via Diskhaler og effektiv konsentrasjon av zanamivir oppnås etter få sekunder7.

Referanser

  1. Mäkelä MJ, Pauksens K, Rostila T et al. Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-Blind, Placebo-controlled European Study. Journal of Infection 2000; 40: 42-48.
  2. Silagy C, Watts R. Zanamivir, a New Targeted Therapy in the Treatment of Influenza; A Patient Perspective Assessed by Questionnaire. Clinical Drug Investigation 2000; 19(2): 111-121.
  3. Preparatomtale godkjent 27.01.00
  4. Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford: Blackwell Science 1998.
  5. Boivin G, Goyette N, Hardy I et al. Rapid Antiviral Effect of Inhaled Zanamivir in the Treatment of Naturally Occurring Influenza in Otherwise Healthy Adults. The Journal of Infectious Diseases 2000; 181: 1471-4.
  6. Statens Institutt for Folkehelse, www.folkehelsa.no
  7. Cass LMR, Brown J, Pickford M et al. Pharmacoscintigraphic Evaluation of Lung Deposition of Inhaled Zanamivir in Healthy Volunteers. Clinical Pharmacokinetics 1999; 36 (Suppl 1): 21-31.
  8. Von Itzstein M, Wu WY, Kok GB et al. Rational Design of Potent Sialidase Based inhibitors of Influenza Virus Replication. Nature, 1993; 363: 418-423.
  9. Woods JM, Bethell RC, Coates JAV et al. 4-Guanidino-2,4-Dideoxy-2,3-Dehydro-N-Acetylneuraminic Acid Is a Highly Effective Inhibitor Both of the Sialidase (Neuraminidase) and of Growth of a Wide Range of Influenza A and B Viruses In Vitro. Antimicrobal Agents and Chemotherapy, 1993; 37(7): 1473-9.
  10. Monto A et al. Treatment of Influenza with Zanamivir is associated with Rapid Resolution of Symptoms. Clinical Therapeutics, 2000; 22 (11): 1294-1305.
  11. The Mist Study Group. Randomised Trial of Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections. The Lancet 1998; 352: 1877-81
  12. Hayden et al. Efficacy and Safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. New Engl J Med 1997: 337; 874-880.
  13. Johnson R, Schweinle JE, Burrough S. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Results of the Valuable-Insights-from-Patients Study. Clinical drug Investigation 2000; 20(5): 327-336.
  14. Freund B, Gravenstein S et al. Zanamivir. A Review of Clinical Safety. Drug Safety 1999; Oct; 21(4): 267-281.
  15. Murphy KR, Eivindson A. et al. Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Cronic Obstructiv Pulmonary Disease. Clin Drug Invest 2000 Nov 20 (5): 337-349.

 

^ Til toppen